G
Guilin Sanjin Pharmaceutical Co Ltd
SZSE:002275
Guilin Sanjin Pharmaceutical Co Ltd
SZSE:002275
Price:
14.72
CNY
-0.2%
Market Closed
Market Cap:
¥8.6B
Relative Value
The Relative Value of one Guilin Sanjin Pharmaceutical Co Ltd stock under the Base Case scenario is 14.35 CNY. Compared to the current market price of 14.72 CNY, Guilin Sanjin Pharmaceutical Co Ltd is Overvalued by 2%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
14.35
CNY
Overvaluation 2%
G
Multiples Across Competitors
Competitors Multiples
Guilin Sanjin Pharmaceutical Co Ltd Competitors
Guilin Sanjin Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
G
|
Guilin Sanjin Pharmaceutical Co Ltd
SZSE:002275
|
8.7B CNY | 4.2 | 16.5 | 14.5 | 14.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
973.8B USD | 14.9 | 47.2 | 31.8 | 33.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
575.5B USD | 6.1 | 21.5 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
277B CHF | 4.6 | 29.8 | 12.6 | 14.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.5B CHF | 5.3 | 21.5 | 13.2 | 17 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
219.8B GBP | 5.3 | 32.7 | 15.6 | 22.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.2B USD | 4.5 | 16 | 10 | 11.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.3 | 9.7 | 11.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.5B USD | 2.5 | 20.3 | 7.5 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.8B USD | 2.6 | 17.5 | 6.9 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
